DGDaniela Guzmán-Rivera

Daniela Guzmán-Rivera

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Daniela Guzmán-Rivera has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Camila López-Torres

    Laboratorio de Plasticidad Metabólica y Bioenergética, Programa de Farmacología Molecular y Clínica, Instituto de Ciencias Biomédicas (ICBM), Facultad de Medicina, Universidad de Chile, Independencia 1027, Casilla 7, Santiago 8380453, Chile

    1 shared publication
  • Charlotte Palominos

    Clinical and Molecular Pharmacology Program, Institute of Biomedical Sciences (ICBM), Faculty of Medicine, University of Chile, Santiago, 8380453, Chile; Network for Snake Venom Research and Drug Discovery, Santiago, Chile

    1 shared publication
  • Felix A. Urra

    Laboratorio de Plasticidad Metabólica y Bioenergética, Núcleo Interdisciplinario de Farmacología e Inmunología, Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile, Santiago 8380453, Chile

    1 shared publication
  • Miguel Cordova-Delgado

    British Columbia Children's Hospital Research Institute Vancouver British Columbia Canada

    1 shared publication
  • Oney Ramírez-Rodríguez

    Laboratory of Chemistry and Biochemistry, Campus Lillo, University of Aysén, Eusebio Lillo 667, Coyhaique 5951537, Chile

    1 shared publication
  • Ramiro Araya-Maturana

    Instituto de Química de Recursos Naturales, Universidad de Talca, Talca 3460000, Chile

    1 shared publication

Latest Publications

  • Open Access

    FRI-1 Is an Anti-Cancer Isoquinolinequinone That Inhibits the Mitochondrial Bioenergetics and Blocks Metabolic Shifts by Redox Disruption in Breast Cancer Cells

    by Miguel Córdova-Delgado, Sebastián Fuentes-Retamal, Charlotte Palominos, Camila López-Torres, Daniela Guzmán-Rivera, Oney Ramírez-Rodríguez, Ramiro Araya-Maturana, Félix A. Urra

    Since breast cancer (BC) cells are dependent on mitochondrial bioenergetics for promoting proliferation, survival, and metastasis, mitochondria highlight as an important target for anticancer drug discovery. FRI-1, methyl 1, 3-dimethyl-5, 8-dioxo-5, 8-dihydro-4-isoquinolinecarboxylate, was previously described as a selective cytotoxic compound on cancer cell lines, however, details on the mechanism of action remain unknown. In this work, we describe that FRI-1 inhibits mitochondrial bioenergetics, producing apoptosis in MCF7 and MDA-MB-231 BC cell lines. FRI-1 decreases the maximal oxygen consumption rate (OCR), Δψm, NADH, and ATP levels, with a notable increase of mitochondrial reactive oxygen species (ROS) production, promoting AMPK activation with pro-survival effects. Moreover, FRI-1 inhibits the metabolic remodeling to glycolysis induced by oligomycin. In isolated tumoral mitochondria, FRI-1 increases Complex I and III-dependent OCR state 2, and this is sensitive to rotenone and antimycin A inhibitor additions, suggesting a redox cycling event. Remarkably, α-ketoglutarate and lipoic acid supplementation reversed and promoted, respectively, the FRI-1-induced apoptosis, suggesting that mitochondrial redox disruption affects 2-oxoglutarate dehydrogenase (OGDH) activity, and this is involved in their anticancer mechanism. Consistent with this, the combination of FRI-1 and CPI-613, a dual inhibitor of redox-sensible tricarboxylic acid (TCA) cycle enzymes PDH and OGDH, produced extensive BC cell death. Taken together, our results suggest that FRI-1 exhibits anticancer effects through inhibition of mitochondrial bioenergetics by redox disruption in BC cells.